Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil for agitation in Alzheimer's disease (CALM-AD)
NCT00142324Phase 4Unknown
- Sponsor
- Institute of Psychiatry, Psychology & Neuroscience
- Start
- Nov 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) comparing Donepezil with Placebo (2 arms). Primary endpoint: Cohen Mansfield Agitation Inventory at 12 weeks. Status: unknown.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00142324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142324.